Arylsulphonyl hydroxamic acids: potent and selective matrix metalloproteinase inhibitors.
A series of novel matrix metalloproteinase inhibitors is described in which selectivity between MMP and 'sheddase' activity has been achieved and which demonstrate potent in vivo activity in models of arthritis and cancer.